Activity-dependent neurotrophic factor: Intranasal administration of femtomolar-acting peptides improve performance in a water maze

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 3, 2000, Pages 1091-1098

  Gozes, Illana ^a   Giladi, Eliezer ^a   Pinhasov, Albert ^a   Bardea, Amos ^a   Brenneman, Douglas E ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTROPHIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOAVAILABILITY; BRAIN FUNCTION; CONTROLLED STUDY; DRUG EFFECT; MAZE TEST; NEUROPROTECTION; NONHUMAN; OPEN READING FRAME; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; TASK PERFORMANCE;

ADMINISTRATION, INTRANASAL; ANIMALS; AZIRIDINES; BIOLOGICAL AVAILABILITY; CHOLINE; CHOLINE O-ACETYLTRANSFERASE; DRUG STABILITY; MALE; MAZE LEARNING; MEMORY DISORDERS; NERVE GROWTH FACTOR; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR;

EID: 0034083868     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bassan M, Zamostiano R, Davidson A, Blatt C, Gibney G, Glazner GW, Brenneman DE and Gozes I (1999) The complete cDNA sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72:1283-1293.
2. Bassan M, Zamostiano R, Davidson A, Wollman Y, Pitman J, Hauser J, Brenneman DE and Gozes I (1998) The identification of secreted heat shock 60 (hsp60)-like protein from rat glial cells and a human neuroblastoma cell line. Neurosci Lett 249:1-4.
3. Brenneman DE and Eiden LE (1986) Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc Natl Acad Sci USA 83:1159-1162.
4. Brenneman DE and Gozes I (1996) A femtomolar-acting neuroprotective peptide. J Clin Invest 97:2299-2307.
5. Brenneman DE, Hauser J, Neale E, Rubinraut S, Fridkin M, Davidson A and Gozes I (1998) Activity-dependent neurotrophic factor: Structure-activity relationships of femtomolar-acting peptides. J Pharmacol Exp Ther 285:619-627.
6. Brenneman DE, Hauser J, Spong CY, Phillips TM, Pert CB and Ruff M (1999) VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death. Brain Res 838:27-36.
7. Brenneman DE, Nicol T, Warren D and Bowers LM (1990) Vasoactive intestinal peptide: A neurotrophic releasing agent and an astroglial mitogen. J Neurosci Res 25:386-394.
8. Brenneman DE, Phillips TM, Festoff BW and Gozes I (1997) Identity of neurotrophic molecules released from astroglia by vasoactive intestinal peptide. Ann NY Acad Sci 814:167-173.
9. Fisher A, Brandeis R, Pittel Z, Karton I, Sapir M, Dachir S, Levy A and Heldman E (1989) (+)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats. Neurosci Lett 102:325-331,
10. Fonnum F (1975) A rapid radiochemical method for the determination of cholinacetyl transferase. J Neurochem 24:407-409.
11. Glazner GW, Gressens P, Lee SJ, Gibney G, Gozes I, Gozes Y, Brenneman DE and Hill JM (1999) Activity-dependent neurotrophic factor: A potent regulator of embryonic growth. Anat Embryol 200:65-71.
12. Glowa JB, Panlilio LV, Brenneman DE, Gozes I, Fridkin M and Hill JM (1992) Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res 570:49-53.
13. Gordon I, Grauer E, Genis I, Sehayek E and Michaelson DM (1995) Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci Lett 199:1-4.
14. Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, Fridkin M and Giladi E (1997a) Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: Implication for early treatment of Alzheimer's disease. J Neurobiol 33:329-342.
15. Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S, Fridkin M and Brenneman DE (1996) Neuroprotective strategy for Alzheimer's disease: Intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci US A 93:427-432.
16. Gozes I and Brenneman DE (1996) Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J Mol Neurosci 7:235-244.
17. Gozes I, Davidson A, Gozes Y, Mascolo R, Barth R, Warren D, Hauser J and Brenneman DE (1997b) Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: Immunological and biological specificity. Brain Res Dev Brain Res 99:167-175.
18. Gozes I, Glowa JR, Brenneman DE, McCune SK, Lee E and Westphal H (1993) Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. J Mol Neurosci 4:185-193.
19. Gozes I, Lilling G, Glazer R, Ticher A, Ashkenazi IE, Davidson A, Rubinraut S, Fridkin M and Brenneman DE (1995) Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J Pharmacol Exp Ther 273:161-167.
20. Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M and Brenneman DE (1991) An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J Pharmacol Exp Ther 257:959-966.
21. Gozes I, Perl O, Giladi E, Davidson A, Ashur-Fabian O, Rubinraut S and Fridkin M (1999) Mapping the active site in vasoactive intestinal peptide to four amino acids: Novel neuropotective drug design. Proc Natl Acad Sci USA 96:4143-4148.
22. Gozea I, Shachter P, Shani Y and Giladi E (1988) Vasoactive intestinal peptide gene expression from embryos to aging rats. Neuroendocrinology 47:27-31.
23. Gressens P, Hill JM, Paindaveine B, Gozes I, Fridkin M and Brenneman DE (1994) Severe microcephally induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J Clin Invest 94:2020-2027.
24. Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M and Evrard P (1997) Vasoactive intestinal peptide prevents excitotoxic death in the marine developing brain. J Clin Invest 100:390-397.
25. Gressens P, Besse L, Robberecht P, Gozes I, Fridkin M and Evrard P (1999) Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives. J Pharmacol Exp Ther 288:1207-1213.
26. Guo Q, Sebastian L, Sopher BL, Miller MW, Glazner GW, Ware CB, Martin GM and Mattson MP (1999) Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc Natl Acad Sci USA 96: 4125-4130.
27. Hill JM, Mervis RF, Politi J, McCune SK, Gozes I, Fridkin M and Brenneman DE (1994) Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Ann NY Acad Sci 739:211-225.
28. Kaiser PK and Lipton SA (1990) VIP-mediated increase in cAMP prevents tetrodotoxin-induced retinal ganglion cell death in vitro. Neuron 5:373-381.
29. Klimaschewski L (1997) VIP - a 'very important peptide' in the sympathetic nervous system? Anat Embryol 196:269-277.
30. Krajnak K, Kashon ML, Rosewell KL and Wise PM (1998) Aging alters the rhythmic expression of vasoactive intestinal polypeptide mRNA but not arginine vasopressin mRNA in the suprachiasmatic nuclei of female rats. J Neurosci 18:4767-4774.
31. Lamberty Y, Gower AJ, Gobert J, Hanin I and Wulfert E (1992) Behavioural, biochemical and histological effects of AF64A following injection into the third ventricle of the mouse. Behav Brain Res 51:165-177.
32. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47-60.
33. Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE and Gozes I (2000) Vasoactive intestinal peptide (VIP) prevents dopamine neurotoxicity in vitro: Possible relevance to neuroprotection in parkinson's disease. Brain Res 854:257-262.
34. Pincus DW, DiCicco-Bloom EM and Black IB (1990) Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuro-blasts. Nature (Lond) 343:564-567.
35. Said SI (1996) Molecules that protect: The defense of neurons and other cells. J Clin Invest 97:2163-2164.
36. Said SI, Berisha HI and Pakbaz H (1996) Excitotoxicity in the lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly (ADP-ribose) polymerase. Proc Natl Acad Sci USA 93:4688-4692.
37. van Reekum K, Black SE, Conn D and Calrke D (1997) Cognition-enhancing drugs in dementia a guide to the near future. Can J Psychiatry 42 (Suppl 1):S35-S50.
38. Wu JY, Henins KA, Gressens P, Gozes I, Fridkin M, Brenneman DE and Hill JM (1997) Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period. Peptides 18:1131-1137.
39. Zamostiano R, Pinhasov A, Bassan M, Perl O, Steingart RA, Atlas R, Brenneman DE and Gozes I (1999) A femtomolar-acting neuroprotective peptide induces intracellular increases in heat shock protein 60: A potential neuroprotective mechanism. Neurosci Lett 264:9-12.
40. Zhou JN, Hofman MA and Swaab DF (1995) VIP neurons in the human SCN in relation sex, age, and Alzheimer's disease. Neurobiol Aging 16:571-576.